|
業務類別
|
Biotechnology |
|
業務概覽
|
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helicalpeptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between -catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types. |
| 公司地址
| 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140 |
| 電話號碼
| +1 617 945-9510 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.parabilismed.com |
| 員工數量
| 176 |
| Dr. Mathai Mammen, M.D.,PhD |
Chairman of the Board, Chief Executive Officer and President |
-- |
19/05/2026 |
| Dr. Rohin Mhatre, PhD |
Chief Technical Operations Officer |
-- |
19/05/2026 |
| Dr. Fawzi Benzaghou, M.D. |
Chief Medical Officer |
-- |
19/05/2026 |
| Dr. Helen Ho, PhD |
Chief Business and Strategy Officer |
-- |
19/05/2026 |
| Mr. Thomas Kotarakos, PhD |
Chief Financial Officer and Principal Accounting Officer |
-- |
19/05/2026 |
| Ms. Teresa Jurgensen |
General Counsel |
-- |
19/05/2026 |
|
|
| Mr. Alexis A. Borisy, A.M. |
Independent Director |
19/05/2026 |
| Dr. Mathai Mammen, M.D.,PhD |
Chairman of the Board, Chief Executive Officer and President |
19/05/2026 |
| Mr. Alan M. Sebulsky |
Independent Director |
19/05/2026 |
| Mr. Edward M. Fitzgerald |
Independent Director |
19/05/2026 |
| Dr. Krishna Yeshwant, M.D. |
Independent Director |
19/05/2026 |
| Dr. Barbara L. Weber, M.D. |
Independent Director |
19/05/2026 |
| Dr. Jake Simson, PhD |
Independent Director |
19/05/2026 |
| Dr. Rick Klausner, M.D. |
Independent Director |
19/05/2026 |
|
|
|
|
